查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1497782

癌症诊断中的人工智慧市场：按组成部分、部署、癌症类型和最终用户 - 2024-2030 年全球预测

AI in Cancer Diagnostics Market by Component (Hardware, Services, Software), Deployment (Cloud, On-Premise), Cancer Type, End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

癌症诊断领域的人工智慧市场规模预计2023年为2.2038亿美元，2024年达到2.6628亿美元，预计2030年将达到8.625亿美元，复合年增长率为21.52%。

癌症诊断中的人工智慧 (AI) 涉及使用先进的演算法和软体来处理、分析和解释医学影像和资料，以进行癌症检测、诊断和预测。这些由人工智慧主导的系统配备了机器学习和深度学习功能，使它们能够从大量肿瘤资料中学习，并随着时间的推移提高准确性和效率。全球人口中癌症盛行率的不断上升以及对个人化医疗的需求不断增长正在推动人工智慧在医疗保健领域的采用。此外，向非侵入性癌症诊断的快速转变，及其在世界各地多个癌症筛检计画中的快速采用，正在推动人工智慧在癌症治疗中的整合。然而，人工智慧整合癌症治疗的高成本以及缺乏训练有素的肿瘤学家正在影响人工智慧在癌症诊断市场的扩张。此外，政府投资支持的癌症诊断技术进步正在为市场成长创造有利可图的机会。

主要市场统计
基准年[2023] 22038万美元
预测年份 [2024] 26628万美元
预测年份 [2030] 8.625 亿美元
复合年增长率（%） 21.52%

区域洞察

在包括美国和加拿大在内的美国地区，对早期检测和个人化医疗的重视正在推动基于人工智慧的癌症诊断的需求。着名的研究机构和公司正在大力投资人工智慧研究，FDA 等监管机构也急于核准人工智慧诊断工具。公司和学术机构提交的人工智慧专利申请反映了用于诊断成像和基因组资料分析的机器学习演算法的创新。一旦解决了对隐私和准确性的担忧，客户通常会接受人工智慧驱动的医疗保健服务。许多欧盟国家正在透过政府倡议在医疗保健领域进行全面的人工智慧研发活动。在该地区，由于人口老化和癌症发病率上升，客户对人工智慧在癌症诊断方面的需求很高。就顾客购买行为而言，欧洲倾向青睐符合严格 GDPR 法规的产品和服务。中东地区对智慧健康技术进行了大量投资，人工智慧癌症诊断工具的市场正在扩大。在亚太地区，随着人口老化推动消费者需求，癌症诊断领域的人工智慧市场正在扩大。在亚太地区，客户越来越精通技术，并对人工智慧医疗保健解决方案持开放态度，政府对人工智慧研究的支持正在为癌症诊断领域的人工智慧建立一个快速成长的市场。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在癌症诊断市场人工智慧中的定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一个综合工具，可以对癌症诊断市场人工智慧供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该领域竞争性质的宝贵见解，包括累积研究期、片段化优势和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对人工智慧在癌症诊断市场中的当前地位进行全面评估，使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界人口癌症盛行率
      • 全球多个癌症筛检计画的招募人数激增
      • 快速过渡到非侵入性癌症诊断
    • 抑制因素
      • 成本高且缺乏训练有素的肿瘤科医生
    • 机会
      • 癌症诊断的技术进步
      • 政府投资人工智慧在癌症诊断和治疗的应用
    • 任务
      • 容易遭受网路攻击和资料外洩
  • 市场区隔分析
    • 组件：大容量测试中心更喜欢能够以最小错误执行大规模资料处理的先进硬体。
    • 癌症类型：脑肿瘤的复杂性和对肿瘤准确分类的需求正在增加基于人工智慧的诊断的重要性。
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章癌症诊断中的人工智慧市场：按组成部分

  • 硬体
  • 服务
  • 软体

第七章癌症诊断中的人工智慧市场：按发展划分

  • 云
  • 本地

第八章以癌症类型诊断癌症的人工智慧市场

  • 脑肿瘤
  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 摄护腺癌
  • 皮肤癌

第九章癌症诊断中的人工智慧市场：按最终用户划分

  • 癌症中心
  • 医院

第10章：美洲癌症诊断的人工智慧市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区癌症诊断人工智慧市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第12章：欧洲、中东和非洲癌症诊断的人工智慧市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • Okin 与默沙东合作开发利用人工智慧的癌症诊断方法
    • ConcertAI 宣布与癌症中心达成协议，透过人工智慧驱动的影像解决方案加速并转变精准肿瘤学
    • 罗氏与 Ibex 和 Amazon Web Services 合作，加速部署人工智慧数位病理解决方案，帮助改善癌症诊断
  • 战略分析和建议

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-B16853776A7C

[193 Pages Report] The AI in Cancer Diagnostics Market size was estimated at USD 220.38 million in 2023 and expected to reach USD 266.28 million in 2024, at a CAGR 21.52% to reach USD 862.50 million by 2030.

Artificial Intelligence (AI) in cancer diagnostics involves the use of advanced algorithms and software to process, analyze, and interpret medical images and data for the detection, diagnosis, and prediction of cancer. These AI-driven systems are equipped with machine learning and deep learning capabilities, which enable them to learn from vast amounts of oncological data, improving their accuracy and efficiency over time. The increasing prevalence of cancer among the global population and the rising need for personalized medicine boost the adoption of AI in the healthcare sector. Moreover, proliferating adoption in several cancer screening programs worldwide, along with the exponential shift towards non-invasive cancer diagnosis, drives AI integration in cancer therapy. However, the high cost of AI-integrated cancer therapies and the shortage of trained oncologists impact the expansion of AI in the cancer diagnostics market. Furthermore, technological improvements in cancer diagnostics supported by government investments create lucrative opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 220.38 million
Estimated Year [2024] USD 266.28 million
Forecast Year [2030] USD 862.50 million
CAGR (%) 21.52%

Regional Insights

In the American region, including the United States & Canada, the demand for AI-based cancer diagnostics is driven by a strong emphasis on early detection and personalized medicine. Prominent institutions and companies are investing heavily in AI research, and regulatory agencies such as the FDA are expediting approvals of AI diagnostic tools. Patent filings in AI from companies and academic institutions reflect the innovation in machine learning algorithms for imaging and genomic data analysis. Customers are generally receptive to AI-driven healthcare services, provided privacy and accuracy concerns are addressed. A host of EU countries engage in comprehensive AI research and development activities in the healthcare sector through government initiatives. The region shows a strong customer need for AI in cancer diagnostics due to aging populations and increased cancer prevalence. In terms of customer purchasing behavior, Europeans tend to favor products and services that comply with stringent GDPR regulations. In the Middle East, with substantial investments in smart health technologies, there's a growing market for AI cancer diagnostic tools. APAC region has a growing market for AI in cancer diagnostics, with its aging population driving consumer needs. In the APAC region, customers are increasingly tech-savvy and open to AI healthcare solutions, while the government's support of AI research has established a burgeoning market for AI in cancer diagnostics.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the AI in Cancer Diagnostics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Prevalence of cancer among the global population
      • Proliferating adoption in several cancer screening programs worldwide
      • Exponential shift towards non-invasive cancer diagnosis
    • Market Restraints
      • High cost and shortage of trained oncologists
    • Market Opportunities
      • Technological improvements in cancer diagnostics
      • Government investments in using AI in cancer diagnostics and treatments
    • Market Challenges
      • Vulnerability to cyberattacks and data breaches
  • Market Segmentation Analysis
    • Component: High-volume testing centers prefer advanced hardware that can handle large-scale data processing with minimal error
    • Cancer Type: Rising significance of AI-driven diagnostic for brain tumors due to complexity & critical need for precise tumor classification
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the AI in Cancer Diagnostics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the AI in Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Owkin Enters Collaboration Agreement With MSD to Develop AI-Powered Diagnostics for Cancer

Biotechnology firm Owkin has solidified a partnership with MSD, known as Merck & Co. in the United States, to pioneer AI-enhanced digital pathology diagnostics tailored for the European Union market. This groundbreaking collaboration aims to refine pre-screening methods for Microsatellite Instability-High (MSI-H), a genomic biomarker critical for prognosticating and guiding treatment in immunotherapy, specifically in cancers such as endometrial, gastric, small intestine, and biliary where MSI-H detection is currently not standard practice despite its significance. [Published On: 2023-12-19]

ConcertAI Announces Agreement with Cancer Center to Accelerate and Transform Precision Oncology Through AI-Enabled Imaging Solutions

ConcertAI has established a pivotal multi-year strategic partnership with Memorial Sloan Kettering Cancer Center (MSK) to focus on driving the advancement and implementation of clinical AI algorithms and enhancing imaging workflow integration within clinical trials, as well as augmenting oncology clinical decisions. MSK heralds these advancements as a catalyst for precise diagnostics and better management of treatment, fueling a transformative shift within the radiology and AI community that promises a leap in cancer diagnosis and patient care. [Published On: 2023-11-14]

Roche Collaborates with Ibex and Amazon Web Services to Accelerate Adoption of AI-Enabled Digital Pathology Solutions to Help Improve Cancer Diagnoses

F. Hoffmann-La Roche Ltd. has announced collaborations with Ibex Medical Analytics and Amazon Web Services to enhance cancer diagnostics through the navify digital pathology platform, which integrates cutting-edge AI tools for improved accuracy and efficiency in diagnosing breast and prostate cancer. These innovative collaborations aim to streamline pathology workflows by providing secure access to AI-driven decision support, enabling pathologists to deliver precise and expedited patient care. [Published On: 2023-10-26]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the AI in Cancer Diagnostics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the AI in Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Aiosyn B.V., Cancer Center.ai, ContextVision AB, Deep Bio Inc., Google LLC by Alphabet Inc., Ibex Medical Analytics Ltd., International Business Machines Corporation, Kheiron Medical Technologies Limited, Lifebit Biotech Ltd, Lunit Inc., Medial EarlySign, Microsoft Corporation, Mindpeak GmbH, Paige AI, Inc., PathAI, Inc., Proscia Inc., Qritive, Quantib B.V., ScreenPoint Medical BV, Siemens Healthineers AG, Tempus Labs, Inc., Therapixel, Visiopharm A/S, Viz.ai, and Xavor Corporation.

Market Segmentation & Coverage

This research report categorizes the AI in Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Component
    • Hardware
    • Services
    • Software
  • Deployment
    • Cloud
    • On-Premise
  • Cancer Type
    • Brain Tumor
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Prostate Cancer
    • Skin Cancer
  • End-user
    • Cancer Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cancer among the global population
      • 5.1.1.2. Proliferating adoption in several cancer screening programs worldwide
      • 5.1.1.3. Exponential shift towards non-invasive cancer diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and shortage of trained oncologists
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological improvements in cancer diagnostics
      • 5.1.3.2. Government investments in using AI in cancer diagnostics and treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Vulnerability to cyberattacks and data breaches
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: High-volume testing centers prefer advanced hardware that can handle large-scale data processing with minimal error
    • 5.2.2. Cancer Type: Rising significance of AI-driven diagnostic for brain tumors due to complexity & critical need for precise tumor classification
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. AI in Cancer Diagnostics Market, by Component

  • 6.1. Introduction
  • 6.2. Hardware
  • 6.3. Services
  • 6.4. Software

7. AI in Cancer Diagnostics Market, by Deployment

  • 7.1. Introduction
  • 7.2. Cloud
  • 7.3. On-Premise

8. AI in Cancer Diagnostics Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Brain Tumor
  • 8.3. Breast Cancer
  • 8.4. Colorectal Cancer
  • 8.5. Lung Cancer
  • 8.6. Prostate Cancer
  • 8.7. Skin Cancer

9. AI in Cancer Diagnostics Market, by End-user

  • 9.1. Introduction
  • 9.2. Cancer Centers
  • 9.3. Hospitals

10. Americas AI in Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific AI in Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa AI in Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Owkin Enters Collaboration Agreement With MSD to Develop AI-Powered Diagnostics for Cancer
    • 13.3.2. ConcertAI Announces Agreement with Cancer Center to Accelerate and Transform Precision Oncology Through AI-Enabled Imaging Solutions
    • 13.3.3. Roche Collaborates with Ibex and Amazon Web Services to Accelerate Adoption of AI-Enabled Digital Pathology Solutions to Help Improve Cancer Diagnoses
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. AI IN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. AI IN CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. AI IN CANCER DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. AI IN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. AI IN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AI IN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CLOUD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CLOUD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON-PREMISE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN TUMOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN TUMOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN AI IN CANCER DIAGNOSTIC